◀ Back to NFKB1

ADCYAP1 — NFKB1

Text-mined interactions from Literome

Delgado et al., J Immunol 2000 : We showed previously that VIP/PACAP inhibit NF-kappaB nuclear translocation through the stabilization of IkappaB and reduce IFN regulatory factor-1 (IRF-1) binding to the regulatory elements found in the IL-12 p40 and inducible NO synthase promoters
Delgado et al., J Biol Chem 2001 (MAP Kinase Signaling System) : First, VIP/PACAP inhibit p65 nuclear translocation and NF-kappa B DNA binding by stabilizing the inhibitor I kappa B alpha ... The VIP/PACAP inhibition of NF-kappa B at various levels and through different transduction pathways could offer a significant advantage over other anti-inflammatory agents
Delgado et al., J Immunol 2001 (Leukemia L1210...) : VIP/PACAP inhibit the expression and/or DNA binding activity of several transcriptional factors involved in FasL expression, i.e., c-myc, NF-kappaB , NF-ATp, and early growth factors (Egr) 2/3
Delgado et al., J Immunol 2001 (Acute Disease...) : The VIP/PACAP inhibition of both chemokine production and of NF-kappaB binding and transactivating activity is mediated through the specific VIP receptor VPAC1, and involves both cAMP dependent and -independent intracellular pathways
Delgado et al., Glia 2002 (Encephalitis) : The VIP/PACAP inhibition of both chemokine production and of NFkB binding is mediated through the specific receptor VPAC1 and involves a cAMP dependent intracellular pathway
Samal et al., Peptides 2007 : PACAP in both developmental and acute regulatory paradigms acts on target genes also regulated by either TNFalpha or TGFbeta, two first messengers acting on transcription mainly through NFkappaB and Smads, respectively